Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.29 USD | +0.48% | -6.43% | -22.70% |
Financials (USD)
Sales 2024 * | 538K | Sales 2025 * | 675K | Capitalization | 22.29M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -48M | EV / Sales 2024 * | 41.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 33 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.98
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | +0.48% | ||
1 week | -6.43% | ||
Current month | -7.89% | ||
1 month | +2.92% | ||
3 months | -8.09% | ||
6 months | +29.94% | ||
Current year | -22.70% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.29 | +0.48% | 1,441 |
24-04-25 | 8.25 | -3.45% | 6,862 |
24-04-24 | 8.545 | -2.51% | 1,600 |
24-04-23 | 8.765 | +2.51% | 955 |
24-04-22 | 8.55 | -3.50% | 1,657 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.70% | 22.29M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ONCT Stock